|
|
Apixaban |
Rivaroxaban |
Dabigatran etexilate |
|
Absorption |
50% |
100% |
Bioav 6.5% Liver activates prodrug |
|
Distribution |
90% PPB |
90% PPB |
35% PPB (low = dialysable) |
|
Metabolism |
Liver CYP (2/3) |
Liver CYP (2/3) |
Liver phase 2 (minimal) |
|
Excretion |
Urine (1/3) Bile |
Urine (1/3) Bile |
Urine (85%) |
|
Half life |
12 hours |
6-12 hours |
12-18 hours |
|
|
Apixaban |
Rivaroxaban |
Dabigatran etexilate |
|
MoA |
Xa inhibitor |
Xa inhibitor |
Thrombin inhibitor |
|
Onset |
30 mins |
30 mins |
30 mins |
|
Duration |
1 day |
1 day |
1-3 days |
|
Coags |
Normal |
↑INR |
↑aPTT |
|
Monitoring |
Xa |
Xa |
TCT (normal = no drug) DTT ECT |
|
Antidote |
Andexanet alpha Ciraparantag FEIBA* |
Andexanet alpha Ciraparantag FEIBA* |
Idarucizumab* Ciraparantag FEIBA* |
*actually available
Feedback welcome at ketaminenightmares@gmail.com